Assignee
FORMA THERAPEUTICS INC
US·123 granted patents·46 pending applications·1,269 citations·filing 2013–2025
Top patents by PatentIndex Score
169 records- 0199US10377726B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·22 cites·10 claims
- 0299US10112915B23-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Oct 30, 2018·41 cites·31 claims
- 0398US10550098B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·17 cites·25 claims
- 0498US10532047B2Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrileFORMA THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2020·12 cites·20 claims
- 0598US10494354B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·17 claims
- 0698US10494353B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·12 claims
- 0798US10472371B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 12, 2019·13 cites·3 claims
- 0898US10472337B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2019·17 cites·12 claims
- 0998US10428031B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 1, 2019·15 cites·20 claims
- 1098US10421731B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·15 cites·19 claims
- 1198US10421732B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·16 cites·13 claims
- 1298US10414752B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·19 cites·20 claims
- 1398US10414738B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·16 cites·20 claims
- 1498US10239845B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Mar 26, 2019·25 cites·42 claims
- 1598US10214501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·38 claims
- 1698US10214500B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·35 claims
- 1798US10208052B1Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2018·Granted Feb 19, 2019·36 cites·10 claims
- 1898US9834539B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Dec 5, 2017·28 cites·108 claims
- 1998US9630922B23-spiro-7-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 25, 2017·49 cites·33 claims
- 2098US9624175B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·25 cites·39 claims
- 2198US9624216B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·26 cites·74 claims
- 2297US11649242B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2021·Granted May 16, 2023·5 cites·4 claims
- 2397US11498913B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2020·Granted Nov 15, 2022·4 cites·18 claims
- 2497US11396513B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2020·Granted Jul 26, 2022·6 cites·8 claims
- 2597US11071725B2Activating pyruvate kinase RFORMA THERAPEUTICS INC·Filed 2020·Granted Jul 27, 2021·8 cites·21 claims
- 2697US10675274B2Activating pyruvate kinase RFORMA THERAPEUTICS INC·Filed 2019·Granted Jun 9, 2020·12 cites·13 claims
- 2797US10513501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·11 cites·20 claims
- 2897US10494352B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 2997US10494351B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 3097US10464910B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·15 claims
- 3197US10464909B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·17 claims
- 3297US10457652B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·12 cites·18 claims
- 3397US10450283B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·16 claims
- 3497US10450284B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·13 claims
- 3597US10442776B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·15 cites·18 claims
- 3697US10336722B2Tetrahydroquinoline compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Jul 2, 2019·22 cites·47 claims
- 3797US10183934B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Jan 22, 2019·27 cites·28 claims
- 3897US9840491B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Dec 12, 2017·22 cites·17 claims
- 3997US9771349B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 26, 2017·27 cites·68 claims
- 4097US9637453B23-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted May 2, 2017·51 cites·31 claims
- 4197US9422281B2Benzopiperazine compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2014·Granted Aug 23, 2016·25 cites·35 claims
- 4296US11299484B2Inhibiting fatty acid synthase (FASN)FORMA THERAPEUTICS INC·Filed 2020·Granted Apr 12, 2022·3 cites·22 claims
- 4396US11111229B2Tetrahydroquinoline compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·4 cites·22 claims
- 4496US11014927B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2018·Granted May 25, 2021·6 cites·3 claims
- 4596US10836771B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 17, 2020·7 cites·2 claims
- 4696US10407418B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 10, 2019·16 cites·19 claims
- 4796US10377767B2Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·16 cites·16 claims
- 4896US10377769B2Benzopiperazine compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·10 cites·28 claims
- 4996US10377773B2Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·18 cites·16 claims
- 5096US10005734B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Jun 26, 2018·25 cites·75 claims
Showing the top 50 of 169 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →